Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801939 | 0.95 | ACE (0.50) | OPRM1ACENTSR2NTSR1F2 | |
| SCHEMBL29801920 | 0.91 | ACE (0.52) | ACENTSR2NTSR1F2 | |
| SCHEMBL29677036 | 0.90 | OPRM1 (0.48) | OPRM1ACENTSR2NTSR1F2 | |
| SCHEMBL29802012 | 0.90 | ACE (0.48) | OPRM1ACENTSR2NTSR1F2 | |
| SCHEMBL31447608 | 0.90 | F2 (0.52) | OPRM1ACENTSR2NTSR1F2 | |
| SCHEMBL29801996 | 0.90 | ACE (0.47) | OPRM1ACENTSR2NTSR1F2 | |
| SCHEMBL29611474 | 0.90 | NTSR2 (0.48) | OPRM1NTSR2NTSR1SORT1 | |
| SCHEMBL29752529 | 0.90 | NTSR2 (0.51) | OPRM1NTSR2NTSR1F2OPRD1 | |
| SCHEMBL8936997 | 0.90 | XIAP (0.51) | OPRM1NTSR2NTSR1OPRD1SORT1 | |
| SCHEMBL8936991 | 0.90 | XIAP (0.51) | OPRM1NTSR2NTSR1OPRD1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731305-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | claimed |
| EP-4665372-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | claimed |
| US-20250066417-A9 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2025-02-27 | — | — | US | claimed |
| WO-2024260465-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-12-26 | — | — | WO | claimed |
| WO-2024169972-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-08-22 | — | — | WO | claimed |
| US-20240218016-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | claimed |
| US-20240182520-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | ENLITISA SHANGHAI PHARMACEUTICAL CO LTD (CN) | 2024-06-06 | — | — | US | claimed |
| US-20240165247-A1 | NEW PEPTIDE CONJUGATES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-05-23 | — | — | US | claimed |
| US-20240124521-A1 | NEW PEPTIDES | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | claimed |
| EP-4308167-A1 | NEW PEPTIDE CONJUGATES | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2024-01-24 | — | — | EP | claimed |
| EP-4069713-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-10-12 | — | — | EP | claimed |
| WO-2022194239-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-09-22 | — | — | WO | claimed |
| WO-2022193185-A1 | NEW CONJUGATES | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2022-09-22 | — | — | WO | claimed |
| WO-2022193186-A1 | NEW DIAGNOSTIC AND THERAPEUTIC AGENTS | JIANGYIN USUN PHARMACEUTICAL CO., LTD. (CN) | 2022-09-22 | — | — | WO | claimed |
| WO-2022194238-A1 | NEW PEPTIDE CONJUGATES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2022-09-22 | — | — | WO | claimed |
| CN-114929726-A | Novel peptides and their use in the treatment of inflammation | 艾缇亚(上海)制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114929259-A | Novel multifunctional oligopeptides | 艾缇亚(上海)制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114929283-A | Novel conjugates of peptides and polysaccharides | 艾缇亚(上海)制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| EP-4028409-A1 | NEW PEPTIDES | Jiangyin Usun Pharmaceutical Co., Ltd. (CN) | 2022-07-20 | — | — | EP | claimed |
| CN-114375298-A | Novel peptides | 江阴贝瑞森制药有限公司 | 2022-04-19 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066417-A9 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | NGLY1, YBX1, VIP | OPRM1 1465/4885ACE 3296/4885NTSR2 1057/4885 |
| US-20240218016-A1 | PEPTIDES AND THEIR USE IN THE TREATMENT OF INFLAMMATION | VIP, ARGLU1, NGLY1 | OPRM1 722/4885ACE 3515/4885NTSR2 1508/4885 |
| US-20240182520-A1 | NEW PEPTIDE-BASED DIAGNOSTIC AND THERAPEUTIC AGENTS | NGLY1, YBX1, VIP | OPRM1 1465/4885ACE 3296/4885NTSR2 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.